PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

BACKGROUND: The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours. METHODS: PR-104 was administered as a one-hour intravenous infusi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: McKeage, Mark J, Jameson, Michael B, Ramanathan, Ramesh K, Rajendran, Joseph, Gu, Yongchuan, Wilson, William R, Melink, Teresa J, Tchekmedyian, N Simon
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2012
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3495895/
https://ncbi.nlm.nih.gov/pubmed/23098625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-496
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items